SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is experiencing intense volatility and downward pressure after Marvell canceled its purchase orders, citing a confidentiality breach caused by the CFO's recent public commentary. Community members are deeply divided between long-term bulls who believe in the company's underlying photonics technology and frustrated investors who are calling for management accountability and questioning the firm's transparency after news of the cancellation was delayed.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending as investors grapple with persistent downward pressure and concerns over potential dilution, despite the company's focus on its upcoming mid-size vehicle platform and continued financial backing from key institutional partners. Community sentiment remains sharply divided between long-term bulls highlighting the company's technical product advantages and skeptics who fear further share price erosion and the threat of bankruptcy or restructuring.

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.

Erasca Inc

Erasca (ERAS) is facing significant market volatility following an 8-K filing that disclosed a Grade 5 fatality, raising investor concerns regarding potential FDA clinical holds and long-term asset viability. Community sentiment is deeply polarized, with critics warning of toxic data and potential bankruptcy, while some long-term holders dismiss the reaction as an over-correction and advocate for buying the dip.

Moolec Science SA engages in the development and production of science-based food ingredients. Its products include pet food, animal feed, and dietary supplements. It operates through the following segments: Seed and Integrated Products, Crop Protection, Crop Nutrition, and Emerging Solutions. The company was founded by Gastón Paladini, Henk Hoogenkamp, and Martin Salinas in 2020 and is headquartered in George Town, Cayman Islands.

Moolec Science SA

Moolec Science is currently the focus of heavy social media speculation and high volatility, with traders highlighting its extremely small float and high borrowing costs as catalysts for potential short-squeeze setups. The community remains deeply divided, balancing excitement over proprietary molecular farming breakthroughs against strong warnings regarding the stock's history of reverse splits and significant cash burn.

Our vision is to create a global exchange using Ethereum blockchain, where everyone on this planet has the opportunity to buy and sell mobile bandwidth in any country just like you buy foreign currencies on FOREX.

DENT

DENT is currently capturing community attention as investors debate its potential for a breakout, with many highlighting its utility in the mobile data space and active development as catalysts for future growth. The community sentiment remains polarized, featuring a mix of long-term holders waiting for a significant price movement and vocal skeptics labeling the asset as a speculative pump-and-dump opportunity.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is trending as investors bet on the commercial viability of its proprietary Perkinamine polymer technology, which is seen as a key solution for high-speed, energy-efficient data center and AI connectivity. Community discussions are heavily focused on the company's potential to displace legacy materials in hyperscale environments, with significant excitement surrounding upcoming industry milestones and partnerships.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently at the center of intense market attention following the release of positive Phase 3 data for its gene-editing therapy and the initiation of a rolling FDA filing. The stock is experiencing extreme volatility as retail investors debate the significance of the clinical results and the implications of a subsequent common stock offering, while the community remains sharply divided over the potential for a short squeeze given the high short interest.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending as the community highlights the recent completion of point-to-point electric air taxi demonstration flights in New York City, which serves as a major real-world proof point for urban air mobility. Investors are actively debating the company's transition from prototype testing to infrastructure integration, with sentiment split between those focused on long-term growth catalysts and those concerned by ongoing execution challenges and stock price volatility.

Rambus, Inc. engages in the provision of cutting-edge semiconductor and Internet Protocol products, spanning memory and interfaces to security, smart sensors and lighting. Its products include Memory Interface Chips, Interface IP, and Security IP. The company was founded by P. Michael Farmwald and Mark A. Horowitz in March 1990 and is headquartered in Sunnyvale, CA.

Rambus Inc.

Rambus Inc. (RMBS) is currently trending as investors weigh mixed quarterly results against the stock's significant long-term potential in AI and data center memory architecture. The community remains divided, with some traders focused on recent volatility and earnings-related sell-offs, while long-term bulls emphasize institutional confidence and the companys pivotal role in the semiconductor supply chain.

X-Energy, Inc. operates as an energy company The firm focuses on modular nuclear reactors and fuel technology for clean energy generation. The company was founded by Kam Ghaffarian and Eben Mulder on 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-energy Inc

X-energy is generating significant investor buzz following its recent IPO, fueled by strong backing from major players like Amazon and interest in its role within the burgeoning AI data center power narrative. The community is actively debating the company's valuation and long-term execution capabilities compared to other nuclear-sector peers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Adherex Technologies Inc. (NASDAQ:FENC) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of Adherex Technologies Inc. (NASDAQ:FENC - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven research firms that are presently covering the stock...

Fennec Pharmaceuticals (TSE:FRX) Stock Price Passes Below Fifty Day Moving Average - Here's What Happened

Fennec Pharmaceuticals (TSE:FRX) Stock Passes Below Fifty Day Moving Average - What's Next...

Adherex Technologies (NASDAQ:FENC) Given "Outperform" Rating at Wedbush

Wedbush reiterated an "outperform" rating and issued a $13.00 target price on shares of Adherex Technologies in a research note on Thursday...

Fennec Pharmaceuticals (TSE:FRX) Shares Cross Below Fifty Day Moving Average   - What's Next?

Fennec Pharmaceuticals (TSE:FRX) Shares Cross Below Fifty Day Moving Average - Here's What Happened...

Adherex Technologies (NASDAQ:FENC) Cut to Hold at Wall Street Zen

Wall Street Zen cut shares of Adherex Technologies from a "buy" rating to a "hold" rating in a research note on Saturday...

Adherex Technologies (NASDAQ:FENC) Director Rosty Raykov Sells 10,946 Shares

Adherex Technologies Inc. (NASDAQ:FENC - Get Free Report) Director Rosty Raykov sold 10,946 shares of Adherex Technologies stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $6.31, for a total value of $69,069.26. Following the completion of the transaction...

HC Wainwright Has Bearish Forecast for FENC Q1 Earnings

Adherex Technologies Inc. (NASDAQ:FENC - Free Report) - Analysts at HC Wainwright dropped their Q1 2026 earnings per share (EPS) estimates for shares of Adherex Technologies in a research note issued...

Equities Analysts Offer Predictions for TSE:FRX Q1 Earnings

Fennec Pharmaceuticals Inc. (TSE:FRX - Free Report) - Stock analysts at HC Wainwright lowered their Q1 2026 earnings estimates for Fennec Pharmaceuticals in a report issued on Monday, March 30th. HC...

HC Wainwright Issues Negative Forecast for TSE:FRX Earnings

Fennec Pharmaceuticals Inc. (TSE:FRX - Free Report) - Research analysts at HC Wainwright dropped their Q3 2026 earnings per share (EPS) estimates for Fennec Pharmaceuticals in a report issued on Monday, March 30th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company...

HC Wainwright Issues Negative Forecast for FENC Earnings

Adherex Technologies Inc. (NASDAQ:FENC - Free Report) - Research analysts at HC Wainwright cut their Q3 2026 EPS estimates for shares of Adherex Technologies in a note issued to investors on Monday, March 30th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings pe...

Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

Current Price	$6.85
Prev Close	$6.84
Open	$6.82
Dividend Yield	0.00%
50-Day Moving Average	$7.29
Beta	0.98
Avg. Volume	227,348.07
PE Ratio	-19.91

52-Week High	$9.92
52-Week Low	$5.65
Market Capitalization	$236.16M
EPS (Annual)	-$0.3409
Price to Book	6.60
Revenue Per Employee	$1.28M

FENC
Fennec Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FENC News

FENCFennec Pharmaceuticals Inc